Trial Profile
A Retrospective, Nonrandomized, Multicentric Study to Evaluate the Long-Term Outcomes of Ranibizumab Monotherapy in Patients with Myopic Choroidal Neovascularization (mCNV)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Adverse reactions; Therapeutic Use
- 18 May 2018 New trial record